A new research increases the hope that oxytocin hormone can be used as a nasal spray to effectively treat people with mental illness. The study recruited 16 healthy adult volunteers, and they examined two different doses of oxytocin and their effects on the perception of social cues. Everyone received four single-dose treatments: placebo, low-dose oxytocin, high-dose oxytocin, and single-dose oxytocin. Oxytocin is given intravenously.

The intravenous dose is used to compare the effects of oxytocin on circulating blood. After each dose, the participants saw the faces of 20 men and 20 women with expressions of anger, happiness, and emotional ambiguity, and were asked to determine how angry or happy people were.

Meanwhile, intravenous treatment had no observable effect on participants, suggesting that intranasally administered oxytocin is a more direct route to the brain. And what about the highest dose of oxytocin? The researchers said it could be more harmful than beneficial. is lower, but still influences behavior, this means a lower risk of influencing other regulatory systems in the body. In fact, very high doses of oxytocin could have the opposite effect on social behavior, ”said Ole, professor at the University of Oslo and author of the study. Andreassen said in a statement. Obviously, this study is limited in that the study involved a very small sample size that healthy people participated in. It’s also important to note that Stanford researchers published a study in the Proceedings of the National Academy of Sciences last year that found that children with autism are no more likely to have autism than other children with low blood oxytocin levels. New researches are showing evidences that can help people with mental illness

PH94B is an odorless Freein neuroactive molecule that binds to chemosensory receptors in the nose and is administered as a nasal spray. Studies have shown that PH94B can reduce anxiety and anxiety, and have an objective effect on heart rate, blood pressure and breathing. The nasal spray allows PH94B to enter the nasal passages and chemosensory receptors directly. In fact, we spray the molecule (PH9B) directly onto the receptors. Because of this direct management, we can use micrograms instead of milligrams to describe the number of such synthetic molecules. We believe that PH94B may be the first on-demand treatment for social anxiety disorder. SAD is a common mental disorder that affects approximately 7% of the U.S. adult population. The only therapies approved by the FDA for the treatment of SAR are various antidepressants. Doctors also prescribe benzodiazepines that are not listed on the label, but benzodiazepines can cause drowsiness/drowsiness, cognitive impairment, and addiction. It seems that it does not have any of these flaws. Since PH94B is a new first-rate drug and there is no FDA-approved Pro-Re-Nata treatment (PRN) for SAD, we want to confirm to the FDA that we are on the same page as the development process and agreement. Start this research sometime in the first half of 2020. We sincerely look forward to promoting the plan. I think it can really help people with social anxiety disorder and actively change their lives, thanks to its rapid onset, route of administration, necessary dosage convenience, and excellent safety compared to current treatment options.

Oxytocin hormone nasal spray device is expected to help people with certain types of mental illness improve social skills. Oxytocin has been shown to play an important role in relieving anxiety and creating satisfaction. The equipment was developed in cooperation with the Norwegian biotechnology company Optinose.

According to the license agreement with the start-up life science company InnarisBio, nasal spray technology for psychedelic and non-psychedelic drugs for the treatment of mental disorders is being developed, and the technology is being developed for clinical use. Harendra Pareh and her team developed a solution-to-gel technology for intranasal administration, which is a liquid solution containing a therapeutic compound that forms a gel when it comes in contact with the nasal mucosa. InnarisBio will cooperate with UniQuest, PhD. Parech of the University of Queensland and their research team worked together to formulate and develop custom Solgel formulations for various psychedelic and non-psychedelic compounds nominated by InnarisBio. Under the terms of the agreement, UniQuest will acquire shares in InnarisBio, as well as the ability to obtain future development and payment for commercial phase and sales licenses.